May 29, 2020

Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

-Bristol Myers Squibb has announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple... Read More
May 29, 2020

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval... Read More
May 29, 2020

Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by c. 80%

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the... Read More
May 28, 2020

Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into... Read More
May 28, 2020

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus recently announced a... Read More
May 28, 2020

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that... Read More
May 20, 2020

LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA)... Read More
May 19, 2020

Roche launches new exome and custom KAPA Target Enrichment portfolio for translational and clinical research applications in sequencing

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of the new KAPA Target Enrichment portfolio, consisting of both exome and custom target... Read More
May 19, 2020

Flatiron Health, Foundation Medicine and Genentech Partner to Launch Novel Prospective Lung Cancer Clinical Study

Flatiron Health, Foundation Medicine, and Genentech, a member of the Roche Group, in partnership with community and academic oncology practices, have launched the Prospective... Read More
May 19, 2020

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines... Read More
May 18, 2020

Thermo Fisher Scientific Response to COVID-19 Expands to Include New Serology Test

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced it will expand its response to the COVID-19 pandemic by developing... Read More
May 18, 2020

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)

Bayer and ArcherDX, Inc. have announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi®... Read More
May 8, 2020

Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program

To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific today announces the SARS-CoV-2 GlobalAccess Sequencing Program for... Read More
May 6, 2020

Blueprint Medicines Reports First Quarter 2020 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided... Read More
May 6, 2020

Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2020. “We... Read More